Share this article
SCOTTSDALE, Ariz., Feb. 3, 2021 /PRNewswire/ Matrix Medical Network
® (Matrix) today announced a collaboration with global biopharmaceutical company AstraZeneca to accelerate a clinical trial in the US for AZD7442, AstraZeneca s long-acting monoclonal antibody (LAAB) combination for the potential prevention of COVID-19. Matrix Clinical Solutions will meet eligible volunteers where they live and work with a fleet of Mobile Health Clinics and skilled clinicians, with a focus on populations more impacted by COVID-19.
Matrix Medical Network Mobile Health Clinic
Matrix is supporting the Phase III clinical trial called STORM CHASER, which will assess the safety and efficacy of AZD7442 for post-exposure prophylaxis in approximately 1,125 participants in the US and UK. Participants in this trial will include adults over 18 years of age following exposure to SARS-COV-2 and who are therefore at appreciable risk of developing COVID-19. The trial will include people liv
Matrix Medical Network Announces the Integration of Biocerna
In-House Testing Capabilities and Significant Expansion Better Position Matrix to Serve Customers
News provided by
Share this article
® (Matrix) today announced the completion of the integration of Biocerna, a state-of-the-art CLIA-certified and CAP-accredited laboratory dedicated to delivering clinical diagnostics tests to improve patients safety and quality of care throughout the U.S. The addition of Biocerna s laboratory and expertise adds dedicated capacity for accurate, rapid testing and processing for Matrix s clients. Since receiving U.S. Food and Drug Administration Emergency Use Authorization in April 2020, Biocerna has processed 99 percent of COVID-19 tests within 24 hours of receipt at the laboratory. Biocerna is located in Fulton, Maryland less than an hour from three major airports, helping to facilitate rapid testing.